Skip to main content
NCD 190.31 · version 1 · Laboratory NCD

NCD 190.31: Prostate Specific Antigen

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026); Lab NCD code lists: October 2026 (effective October 1, 2026). Next CMS release: weekly, every Thursday for the Medicare Coverage Database NCDs; January 1, 2027 (quarterly update) for the Lab NCD code lists.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 190.31

Benefit category
Diagnostic Laboratory Tests
Effective date
11/25/2002
Implemented 01/01/2003
Transmittal
Transmittal 17
Versions published
1
Manual section
190
Pathology and Laboratory, NCD Manual (Pub. 100-03) chapter 1 part 3
Lab edit list
51 covered ICD-10
233 non-covered

TL;DR

NCD 190.31 sets Medicare's national policy for prostate specific antigen under the benefit category "Diagnostic Laboratory Tests", effective 11/25/2002 and implemented 01/01/2003. PSA is of proven value in differentiating benign from malignant disease in men with lower urinary tract signs and symptoms (e.g., hematuria, slow urine stream, hesitancy, urgency, frequency, nocturia and incontinence) as well as with patients with palpably… As a laboratory NCD it carries a national ICD-10 edit list: 51 diagnosis codes support medical necessity and 233 are denied, applied automatically by every Medicare contractor to 1 procedure code.

Item or service described

Prostate Specific Antigen (PSA), a tumor marker for adenocarcinoma of the prostate, can predict residual tumor in the post-operative phase of prostate cancer. Three to six months after radical prostatectomy, PSA is reported to provide a sensitive indicator of persistent disease. Six months following introduction of antiandrogen therapy, PSA is reported as capable of distinguishing patients with favorable response from those in whom limited response is anticipated.

PSA when used in conjunction with other prostate cancer tests, such as digital rectal examination, may assist in the decision making process for diagnosing prostate cancer. PSA also, serves as a marker in following the progress of most prostate tumors once a diagnosis has been established. This test is also an aid in the management of prostate cancer patients and in detecting metastatic or persistent disease in patients following treatment.

Indications and limitations of coverage

Indications

PSA is of proven value in differentiating benign from malignant disease in men with lower urinary tract signs and symptoms (e.g., hematuria, slow urine stream, hesitancy, urgency, frequency, nocturia and incontinence) as well as with patients with palpably abnormal prostate glands on physician exam, and in patients with other laboratory or imaging studies that suggest the possibility of a malignant prostate disorder. PSA is also a marker used to follow the progress of prostate cancer once a diagnosis has been established, such as in detecting metastatic or persistent disease in patients who may require additional treatment. PSA testing may also be useful in the differential diagnosis of men presenting with as yet undiagnosed disseminated metastatic disease.

Limitations

Generally, for patients with lower urinary tract signs or symptoms, the test is performed only once per year unless there is a change in the patient's medical condition.

Testing with a diagnosis of in situ carcinoma is not reasonably done more frequently than once, unless the result is abnormal, in which case the test may be repeated once.

Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

Text reproduced from the CMS Medicare Coverage Database record for NCD 190.31 version 1. View the original on cms.gov.

Laboratory NCD code lists (October 2026)

Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list holds 51 covered and 233 non-covered ICD-10-CM codes; any code not on the list does not support medical necessity.

1 procedure code are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.

Procedure codes subject to NCD 190.31
CodeCode set
84153CPT (descriptor licensed by AMA)

What Medicare pays for these tests: 1 of the 1 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $18.39, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.

Clinical Laboratory Fee Schedule amounts for the codes NCD 190.31 edits, October 2026
CodeCLFS amountWith QWPricing
84153$18.39—national payment amount
Source: CMS Clinical Laboratory Fee Schedule 26CLABQ4. Every code range and the October changes are on the Clinical Laboratory Fee Schedule page.

The first 40 of 51 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.

Covered ICD-10-CM codes for NCD 190.31 (sample)
ICD-10-CMDescriptionEffective
C61Malignant neoplasm of prostate2015-10-01
C67.5Malignant neoplasm of bladder neck2015-10-01
C77.4Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes2015-10-01
C77.5Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes2015-10-01
C77.8Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions2015-10-01
C79.51Secondary malignant neoplasm of bone2015-10-01
C79.52Secondary malignant neoplasm of bone marrow2015-10-01
C79.82Secondary malignant neoplasm of genital organs2015-10-01
D07.5Carcinoma in situ of prostate2015-10-01
D40.0Neoplasm of uncertain behavior of prostate2015-10-01
D49.511Neoplasm of unspecified behavior of right kidney2016-10-01
D49.512Neoplasm of unspecified behavior of left kidney2016-10-01
D49.519Neoplasm of unspecified behavior of unspecified kidney2016-10-01
D49.59Neoplasm of unspecified behavior of other genitourinary organ2016-10-01
M33.03Juvenile dermatomyositis without myopathy2017-10-01
M33.13Other dermatomyositis without myopathy2017-10-01
M33.93Dermatopolymyositis, unspecified without myopathy2017-10-01
N13.9Obstructive and reflux uropathy, unspecified2015-10-01
N32.0Bladder-neck obstruction2015-10-01
N40.0Benign prostatic hyperplasia without lower urinary tract symptoms2015-10-01
N40.1Benign prostatic hyperplasia with lower urinary tract symptoms2015-10-01
N40.2Nodular prostate without lower urinary tract symptoms2015-10-01
N40.3Nodular prostate with lower urinary tract symptoms2015-10-01
N41.9Inflammatory disease of prostate, unspecified2015-10-01
N42.9Disorder of prostate, unspecified2015-10-01
R31.0Gross hematuria2015-10-01
R31.1Benign essential microscopic hematuria2015-10-01
R31.21Asymptomatic microscopic hematuria2016-10-01
R31.29Other microscopic hematuria2016-10-01
R31.9Hematuria, unspecified2015-10-01
R32Unspecified urinary incontinence2015-10-01
R33.9Retention of urine, unspecified2015-10-01
R35.0Frequency of micturition2015-10-01
R35.1Nocturia2015-10-01
R39.11Hesitancy of micturition2015-10-01
R39.12Poor urinary stream2015-10-01
R39.14Feeling of incomplete bladder emptying2015-10-01
R39.15Urgency of urination2015-10-01
R39.16Straining to void2015-10-01
R93.5Abnormal findings on diagnostic imaging of other abdominal regions, including retroperitoneum2015-10-01

233 diagnosis codes deny automatically under this NCD; the first 20 are shown.

Non-covered ICD-10-CM codes for NCD 190.31 (sample)
ICD-10-CMDescription
R99Ill-defined and unknown cause of mortality
Z00.00Encounter for general adult medical examination without abnormal findings
Z00.01Encounter for general adult medical examination with abnormal findings
Z00.110Health examination for newborn under 8 days old
Z00.111Health examination for newborn 8 to 28 days old
Z00.121Encounter for routine child health examination with abnormal findings
Z00.129Encounter for routine child health examination without abnormal findings
Z00.5Encounter for examination of potential donor of organ and tissue
Z00.6Encounter for examination for normal comparison and control in clinical research program
Z00.70Encounter for examination for period of delayed growth in childhood without abnormal findings
Z00.71Encounter for examination for period of delayed growth in childhood with abnormal findings
Z00.8Encounter for other general examination
Z02.0Encounter for examination for admission to educational institution
Z02.1Encounter for pre-employment examination
Z02.2Encounter for examination for admission to residential institution
Z02.3Encounter for examination for recruitment to armed forces
Z02.4Encounter for examination for driving license
Z02.5Encounter for examination for participation in sport
Z02.6Encounter for examination for insurance purposes
Z02.71Encounter for disability determination

Changed in October 2026

The October 2026 lab NCD release made no change to this NCD's ICD-10-CM list: no code was added, removed or given a new result against January 2026.

Codes on this NCD's list by release: October 2025: 284 · January 2026: 284 · October 2026: 284. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.

Local policies that build on this NCD

3 active Local Coverage Determinations cite NCD 190.31 among their related national policies. An LCD may not conflict with the national determination; read it for the contractor's documentation and coding detail in that jurisdiction.

  • 4Kscore Test Algorithm, LCD L37792 · Novitas Solutions, Inc.
  • L37798 4Kscore Test Algorithm · First Coast Service Options, Inc.
  • L39284 Prostate Cancer Detection with IsoPSA® · CGS Administrators, LLC

Revision history

07/2004 - Published NCD in the NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance now published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)

07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 190.31

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 190.31

What does NCD 190.31 cover?

PSA is of proven value in differentiating benign from malignant disease in men with lower urinary tract signs and symptoms (e.g., hematuria, slow urine stream, hesitancy, urgency, frequency, nocturia and incontinence) as well as with patients with palpably abnormal prostate glands on physician exam, and in patients with other laboratory or imaging studies that suggest the possibility of a malignant prostate… The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 190.31 take effect?

The current version (1) is effective 11/25/2002, implemented 01/01/2003, published in transmittal 17. This is the only published version.

Does a Local Coverage Determination override NCD 190.31?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Which diagnosis codes are covered under NCD 190.31?

The October 2026 laboratory NCD edit list contains 51 ICD-10-CM codes that support prostate specific antigen (for example C61 Malignant neoplasm of prostate; C67.5 Malignant neoplasm of bladder neck; C77.4 Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes) and 233 codes that deny. The list applies to 84153.

How often does the lab NCD code list for 190.31 change?

CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.

CMS guidance

Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.